Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.46 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.46 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.46 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.35 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3363679 | 1.00 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| Hydrochloric Acid SCHEMBL384984 | 1.00 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL218064 | 0.97 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL29265359 | 0.97 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL384165 | 0.97 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL382975 | 0.97 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL15401713 | 0.94 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL20581837 | 0.94 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| Methane SCHEMBL28827281 | 0.94 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL15401674 | 0.94 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114426497-A | Preparation method of trans-4-aminocyclohexanecarboxylic acid hydrochloride | 泰州精英化成医药科技有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-109824545-B | Preparation method of trans-4-N-Boc-aminocyclohexane carboxylic acid | 泰州精英化成医药科技有限公司 | 2021-02-26 | — | — | CN | claimed |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| CN-114174303-B | Macrocyclic compounds as STING agonists and methods and uses thereof | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4380560-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Contineum Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11932599-B2 | Ferroptosis inducing compound, compositions comprising the same, and methods of inducing ferroptosis | UNIVERSITY OF MASSACHUSETTS (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642392-A | Preparation and application of compounds with immunoregulation function | 上海轶诺药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| WO-2007127382-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
| US-5700801-A | ANTIINFLAMMATORY AGENTS, BONE DISORDERS | KARL THOMAE, GMBH (DE) | 1997-12-23 | — | — | US | disclosed |
| EP-0516980-B1 | Novel 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors | MERRELL PHARMA INC (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5252601-A | 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0516980-A1 | Novel 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | GABRP 4674/4885GABRD 4731/4885GABRA1 4601/4885 |
| US-11932599-B2 | Ferroptosis inducing compound, compositions comprising the same, and methods of inducing ferroptosis | AIFM2, AIFM1, FECH | GABRP 4754/4885GABRD 4839/4885GABRA1 4479/4885 |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | GABRP 643/4885GABRD 2702/4885GABRA1 1636/4885 |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | TPMT, MGMT, SMAD3 | GABRP 4756/4885GABRD 4747/4885GABRA1 4606/4885 |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | GABRP 2435/4885GABRD 2574/4885GABRA1 2537/4885 |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | GABRP 4716/4885GABRD 4759/4885GABRA1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.